scout

Maria A. Rodriguez, MD

Articles by Maria A. Rodriguez, MD

Irinotecan in Relapsed or Refractory Non-Hodgkin’s Lymphomas

ByAndreas H. Sarris, MD, PhD,Alexandria T. Phan, MD,A. Goy, MD,Jorge Romaguera, MD,Fredrick B. Hagemeister, MD,Maria A. Rodriguez, MD,Peter Mclaughlin, MD,Barbara Pro, MD,L. Jeffrey Medeiros, MD,Barry Samuels, MD,Ofie Mesina, RN,A. W. Bleyer, MD,Fernando Cabanillas, MD

Because irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity, we investigated its activity in relapsed or refractory non-Hodgkin’s lymphomas (NHLs). Irinotecan at 300 mg/m² IV was administered every 21 days with intensive loperamide management of diarrhea.

Irinotecan in Relapsed or Refractory Non-Hodgkin’s Lymphoma

ByAndreas H. Sarris, MD, PhD,Jorge Romaguera, MD,Fredrick B. Hagemeister, MD,Maria A. Rodriguez, MD,Peter Mclaughlin, MD,Barbara Pro, MD,Anas Younes, MD,Ofie Mesina, RN,Fernando Cabanillas, MD,L. Jeffrey Medeiros, MD,Barry Samuels, MD

Irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity. Various schedules and doses have been studied, and major complications were delayed diarrhea and

Latest Updated Articles



Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us